Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-54389
ACS Chem Neurosci 2017 Aug 16;88:1681-1687. doi: 10.1021/acschemneuro.7b00117.
Show Gene links Show Anatomy links

Subtype-Specific Agonists for NMDA Receptor Glycine Binding Sites.

Maolanon AR , Risgaard R , Wang SY , Snoep Y , Papangelis A , Yi F , Holley D , Barslund AF , Svenstrup N , Hansen KB , Clausen RP .


???displayArticle.abstract???
A series of analogues based on serine as lead structure were designed, and their agonist activities were evaluated at recombinant NMDA receptor subtypes (GluN1/2A-D) using two-electrode voltage-clamp (TEVC) electrophysiology. Pronounced variation in subunit-selectivity, potency, and agonist efficacy was observed in a manner that was dependent on the GluN2 subunit in the NMDA receptor. In particular, compounds 15a and 16a are potent GluN2C-specific superagonists at the GluN1 subunit with agonist efficacies of 398% and 308% compared to glycine. This study demonstrates that subunit-selectivity among glycine site NMDA receptor agonists can be achieved and suggests that glycine-site agonists can be developed as pharmacological tool compounds to study GluN2C-specific effects in NMDA receptor-mediated neurotransmission.

???displayArticle.pubmedLink??? 28514141
???displayArticle.pmcLink??? PMC5559341
???displayArticle.link??? ACS Chem Neurosci
???displayArticle.grants??? [+]


References [+] :
Bräuner-Osborne, Ligands for glutamate receptors: design and therapeutic prospects. 2000, Pubmed